Biotech Bear Market: Another Bad Day IBB Down 2.9%…Update-1 Regeneron (REGN)
Update-1 May 5 ...Biotechs Stable Today...IBB up 0.45%, XBI down 0.53% Regeneron Pharmaceuticals (REGN) up 4.74% on sales growth,but missed on EPS. Regeneron (REGN) raised 2016 sales estimates for Eyelea(R) to a 20-25% increase based on Q1 sales of $781M. Total Revenues were $1.2B including...
Failed Biotech Rally: Latest Biotech Earnings Don’t Help…ALXN AMGN CELG GILD…Update-1
Update-1 May 2 Biotechs Stop Slide...IBB up 1.12%...Green Screen Day Healthcare Stocks Regain Footing... XLV up 0.57% Biotech stocks moved up after a five day swoon but are still flat after one month. Most large caps were green with decent gains in Celgene (CELG) and Regeneron (REGN). A good...
Immuno-Oncology: New Products Provide Growth and Value: ABBV BMY
Immuno-Oncology: Sweet Spot in a Biotech Bear Market We will continue to track large cap biopharma Q1 earnings looking for value+growth ideas. The financial metrics will be tracked as we did in our original post, "Large Cap Winners and Losers" on February 16 near the 2016 bottom for the sector....
Biotech Bear Market: Can Diversified Healthcare Funds Beat ETFS?…Part-1
Biotech Bear Market: XLV ---A Large Cap Healthcare ETF Outperforms We have compared the performance of top mutual funds in the past and thought it would be interesting to see what happens in a bear market which began in September of 2015. Our last review was in February of 2015 when the bull...
Biotech Recovery Rally: Steady as She Goes-Biogen Rallies on Earnings…Update-1
Expect Modest Rally in Biotechs Through Q1 Earnings As of mid-day trading 1P EDT with flat NASDAQ Update at close: biotechs held onto gains despite a mild sell-off for the Dow and S&P with NASDAQ flat. Biogen (BIIB) gained a tad more up 5.16%. From here we'd like to see more rotation into...